Premium
CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6‐Mediated Drug Metabolism in Healthy Human Liver Tissue
Author(s) -
Ning Miaoran,
Duarte Julio D.,
Rubin Leah H.,
Jeong Hyunyoung
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1032
Subject(s) - cyp2d6 , biology , phenotype , drug metabolism , genotype , drug , pharmacology , genetics , gene
CYP2D6 genetic polymorphisms are considered a major contributor to the large interindividual variability in CYP2D6‐mediated drug metabolism, but fail to explain a significant portion of the variability. The aim of this study was to assess the ability of the CYP2D6 activity score (AS) estimated from CYP2D6 genotype to predict CYP2D6 expression and enzyme activity. The CYP2D6 gene region was sequenced in 115 healthy human liver tissue samples to determine their CYP2D6 AS. Additionally, CYP2D6 enzyme activity, protein, and mRNA levels were estimated. CYP2D6 AS explained 23% of the interindividual variability in CYP2D6 activity, but only 7.5% in tissues assigned AS 1–2. The CYP2D6 protein level was found to be the major determinant of CYP2D6 activity, explaining 59% of variability. These findings suggest that while CYP2D6 AS is a good predictor of poor metabolizer phenotype, additional nongenetic factors may govern the rate of CYP2D6‐mediated metabolism in those without the poor metabolizer phenotype.